John Kastelein

Equibles does not estimate personal net worth.

Get an email with a short summary when NewAmsterdam Pharma Co N.V. publishes a filing, an earnings call transcript or a press release.

Get NAMS alerts

About John Kastelein

The proxy statement of NewAmsterdam Pharma Co N.V. reports total compensation of $2,978,571 for John Kastelein in fiscal 2023, including a base salary of $459,346. NewAmsterdam Pharma Co N.V. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at NewAmsterdam Pharma Co N.V. includes Michael Davidson (CEO), Willian H. Lewis, J.D., M.B.A. (Chairman), Ian Somaiya (CFO) and 4 others.

Affiliation history

NewAmsterdam Pharma Co N.V. (NAMS)
Proxy statement

Current
Start not stated–present

Last confirmed May 6, 2026

Company network

NewAmsterdam Pharma Co N.V.

NAMS

Current role

Biotechnology · Healthcare

Leadership on record at NewAmsterdam Pharma Co N.V.

Michael Davidson CEO
Willian H. Lewis, J.D., M.B.A. Chairman
Ian Somaiya CFO
Robert W. Gunning Chief Accounting Officer
Adele Gulfo Board Member
Mark C. McKenna Board Member
Wouter Joustra Board Member

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2023	NewAmsterdam Pharma Co N.V. (NAMS)	M.D., Ph.D. FESC Chief Scientific Officer	$459,346	$218,412	—	$2,300,813	—	—	$2,978,571

Recent activity

No call appearances or filed executive changes recorded yet.